Lifecore Biomedical Inc
NASDAQ:LFCR
Lifecore Biomedical Inc
Net Issuance of Debt
Lifecore Biomedical Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Net Issuance of Debt
-$6.9m
|
CAGR 3-Years
-140%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hershey Co
NYSE:HSY
|
Net Issuance of Debt
$376.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
|
|
General Mills Inc
NYSE:GIS
|
Net Issuance of Debt
$1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Kellogg Co
NYSE:K
|
Net Issuance of Debt
-$36m
|
CAGR 3-Years
51%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Net Issuance of Debt
-$24m
|
CAGR 3-Years
85%
|
CAGR 5-Years
58%
|
CAGR 10-Years
32%
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Net Issuance of Debt
-$1.2B
|
CAGR 3-Years
-110%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-19%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Net Issuance of Debt?
Net Issuance of Debt
-6.9m
USD
Based on the financial report for Nov 24, 2024, Lifecore Biomedical Inc's Net Issuance of Debt amounts to -6.9m USD.
What is Lifecore Biomedical Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-140%
Over the last year, the Net Issuance of Debt growth was -39%. The average annual Net Issuance of Debt growth rates for Lifecore Biomedical Inc have been -140% over the past three years .
You don't have any saved screeners yet